GALETTA, DIANA URANIA
GALETTA, DIANA URANIA
Efficacy of Pembrolizumab Monotherapy in Patients with or without Brain Metastases from Advanced Non-Small Cell Lung Cancer with a PD-L1 Expression ≥50%
2020 Metro, G.; Banna, G. L.; Signorelli, D.; Gili, A.; Galetta, D.; Galli, G.; Economopoulou, P.; Roila, F.; Friedlaender, A.; Camerini, A.; Christopoulou, A.; Cantale, O.; De Toma, A.; Pizzutilo, P.; Jimenez, B.; Collazo-Lorduy, A.; Calles, A.; Baxevanos, P.; Linardou, H.; Kosmidis, P.; Giannarelli, D.; Mountzios, G.; Addeo, A.
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab
2020 Friedlaender, A.; Metro, G.; Signorelli, D.; Gili, A.; Economopoulou, P.; Roila, F.; Banna, G.; De Toma, A.; Camerini, A.; Christopoulou, A.; Lo Russo, G.; Banini, M.; Galetta, D.; Jimenez, B.; Collazo-Lorduy, A.; Calles, A.; Baxevanos, P.; Linardou, H.; Kosmidis, P.; Mountzios, G.; Garassino, M. C.; Addeo, A.
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 >= 50% who progress on first-line immunotherapy: real-world data from a European cohort
2019 Metro, G.; Addeo, A.; Signorelli, D.; Gili, A.; Economopoulou, P.; Roila, F.; Banna, G.; De Toma, A.; Cobo, J. R.; Camerini, A.; Christopoulou, A.; Russo, G. L.; Banini, M.; Galetta, D.; Jimenez, B.; Collazo-Lorduy, A.; Calles, A.; Baxevanos, P.; Linardou, H.; Kosmidis, P.; Garassino, M. C.; Mountzios, G.
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy
2021 Mountzios, G.; de Toma, A.; Economopoulou, P.; Friedlaender, A.; Banini, M.; Lo Russo, G.; Baxevanos, P.; Roila, F.; Banna, G. L.; Christopoulou, A.; Jimenez, B.; Collazo-Lorduy, A.; Linardou, H.; Calles, A.; Galetta, D.; Addeo, A.; Camerini, A.; Pizzutilo, P.; Kosmidis, P.; Garassino, M. C.; Proto, C.; Signorelli, D.; Metro, G.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Efficacy of Pembrolizumab Monotherapy in Patients with or without Brain Metastases from Advanced Non-Small Cell Lung Cancer with a PD-L1 Expression ≥50% | 2020 | Metro, G.; Banna, G. L.; Signorelli, D.; Gili, A.; Galetta, D.; Galli, G.; Economopoulou, P.; Roila, F.; Friedlaender, A.; Camerini, A.; Christopoulou, A.; Cantale, O.; De Toma, A.; Pizzutilo, P.; Jimenez, B.; Collazo-Lorduy, A.; Calles, A.; Baxevanos, P.; Linardou, H.; Kosmidis, P.; Giannarelli, D.; Mountzios, G.; Addeo, A. | |
| Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab | 2020 | Friedlaender, A.; Metro, G.; Signorelli, D.; Gili, A.; Economopoulou, P.; Roila, F.; Banna, G.; De Toma, A.; Camerini, A.; Christopoulou, A.; Lo Russo, G.; Banini, M.; Galetta, D.; Jimenez, B.; Collazo-Lorduy, A.; Calles, A.; Baxevanos, P.; Linardou, H.; Kosmidis, P.; Mountzios, G.; Garassino, M. C.; Addeo, A. | |
| Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 >= 50% who progress on first-line immunotherapy: real-world data from a European cohort | 2019 | Metro, G.; Addeo, A.; Signorelli, D.; Gili, A.; Economopoulou, P.; Roila, F.; Banna, G.; De Toma, A.; Cobo, J. R.; Camerini, A.; Christopoulou, A.; Russo, G. L.; Banini, M.; Galetta, D.; Jimenez, B.; Collazo-Lorduy, A.; Calles, A.; Baxevanos, P.; Linardou, H.; Kosmidis, P.; Garassino, M. C.; Mountzios, G. | |
| Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy | 2021 | Mountzios, G.; de Toma, A.; Economopoulou, P.; Friedlaender, A.; Banini, M.; Lo Russo, G.; Baxevanos, P.; Roila, F.; Banna, G. L.; Christopoulou, A.; Jimenez, B.; Collazo-Lorduy, A.; Linardou, H.; Calles, A.; Galetta, D.; Addeo, A.; Camerini, A.; Pizzutilo, P.; Kosmidis, P.; Garassino, M. C.; Proto, C.; Signorelli, D.; Metro, G. |